Clinical trials: Mood
Bipolar Depression, Treatment Resistant Depression
Intensive TMS for Bipolar Depression
The research study is being conducted to test whether using high dose spaced theta-burst rTMS (a form of transcranial magnetic stimulation) produces a significant reduction in depressive symptoms compared with sham.
- Trial name
- NCT05228457
- Testing
- Intensive intermittent theta-burst stimulation (iTBS)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pennsylvania
Attention-Deficit/Hyperactivity Disorder
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
- Trial name
- NCT06185985
- Testing
- SPN-812
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
- Trial name
- NCT00775203
- Testing
- Trazodone Hydrochloride (HCl) Extended-Release Tablets
- Where
- 36 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Labopharm Inc.
Bipolar Disorder
Bipolar Transcranial Alternating Current Stimulation (tACS)
The purpose of this clinical trial is to measure the safety and effectiveness of a non-invasive brain stimulation device called Transcranial Alternating Current Stimulation (tACS) in participants with bipolar disorder (BD).
- Trial name
- NCT05480124
- Testing
- tACS brain stimulation treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Michigan
Affective Disorders
Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
The purpose of this study is to compare ziprasidone (Geodon) monotherapy for the treatment of psychotic major depression (PMD)with an antidepressant/antipsychotic combined therapy.
- Trial name
- NCT00340379
- Testing
- Ziprasidone, Sertraline, Haloperidol
- Where
- 3 sites in United States, Egypt and 1 more
- Volunteers
- 72 people
- Sponsor
- Duke University
Major Depressive Disorder
Contact: Developing New Clinical Management Strategies
The goal of this study is to develop new methods of administering antidepressant medications that will result in improved drug/placebo separation in randomized controlled trials (RCTs) for Major Depressive Disorder (MDD) and…
- Trial name
- NCT03812588
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New York State Psychiatric Institute
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Epilepsy, Bipolar Disorder
Lamotrigine Pregnancy Registry (LAM05)
Antiepileptic drugs (AEDs) are not indicated for use in pregnancy. However, women with epilepsy, and other approved indications including bipolar disorder, may require or be unintentionally exposed to AEDs during pregnancy.
- Trial name
- NCT01064297
- Testing
- Lamotrigine monotherapy, Lamotrigine polytherapy including valproate, Lamotrigine polytherapy without valproate
- Volunteers
- 3,416 people
- Sponsor
- GlaxoSmithKline
Stress Disorders, Post-Traumatic, PTSD
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
- Conditions
- Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
- Trial name
- KetPTSD (NCT00749203)
- Testing
- Midazolam, Ketamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Dennis Charney
Premenstrual Syndrome
Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder
This study will evaluate the effectiveness of flutamide in reducing symptoms of premenstrual dysphoric disorder.
- Trial name
- NCT00611923
- Testing
- Flutamide
- Volunteers
- 115 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
- Trial name
- VLZ-MD-23 (NCT02436239)
- Testing
- Vilazodone
- Where
- 56 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire I (NCT03039192)
- Testing
- Esketamine, Standard of Care
- Where
- 56 sites in United States, Bulgaria and 9 more
- Volunteers
- 226 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
The BIomarker Guided (BIG) Study for Depression
Cognitive impairments contribute significantly to psychosocial dysfunction in major depressive disorder (MDD) and respond poorly to conventional antidepressants, yet selective treatments targeted to these impairments are lacking.
- Trial name
- NCT04181736
- Testing
- Guanfacine Tablets
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Bipolar Depression
Brexpiprazole for Bipolar Depression
The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state.
- Trial name
- NCT03427892
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder, Menopause
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
HYPOTHESIS: Pregnenolone administration will be associated with greater reduction in depressive symptom severity than placebo in women with current mMDD.
- Conditions
- Major Depressive Disorder, Menopause, Perimenopause
- Trial name
- NCT03505905
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Bipolar Disorder, Bipolar Affective Psychosis
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
The primary purpose of the study is to assess the efficacy of Quetiapine extended release 600mg per day either as monotherapy or combined therapy in the treatment of patients with mania associated to Bipolar disorder.
- Conditions
- Bipolar Disorder, Bipolar Affective Psychosis, Mania, Manic Disorder
- Trial name
- EMMY (NCT00521365)
- Testing
- Quetiapine 600mg
- Where
- 7 sites in Mexico
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Psychomotor Retardation, Psychomotor Slowing
Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior.
- Conditions
- Psychomotor Retardation, Psychomotor Slowing, Schizophrenia and Related Disorders, Major Depressive Disorder
- Trial name
- NCT03275766
- Testing
- DLPFC facilitatory, SMA inhibitory, SMA facilitatory
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Bern
Major Depressive Disorder, Suicidal Ideation
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
The study aims to use a combined clinical and translational approach to identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment.The primary…
- Trial name
- AFSP (NCT01134731)
- Testing
- paliperidone, lithium
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.